A Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study Comparing TPI-120 and Neulasta® Administered Through Subcutaneous Route in Healthy Adult Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Maximum observed concentration (Cmax)
研究概览
简要总结
This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).
All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.
详细描述
The current study design was prepared to assess and compare the PK, PD, safety, tolerability of the Adello biosimilar candidate, TPI-120 and the US-licensed reference product, Neulasta® after administering a single subcutaneous 2 mg dose in healthy adult subjects in a crossover design. The primary PK parameters are AUC0-t, AUC0-inf, and Cmax, and the primary PD parameters are baseline-corrected AUEC0-t and Emax for ANC.
This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).
All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
This is double blind study so participat healthy subjects and investigators both would be blinded
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to dosing), 19 - 55 years of age (inclusive), with body mass index (BMI) ≥ 19 and ≤ 30 kg/m2, and body weight not < 50 kg or > 100 kg at the time of screening.
- •Healthy as defined by:
- •The absence of clinically significant (in the opinion of the PI/designee) illness or surgery within 4 weeks prior to dosing.
- •The absence of a clinically significant (in the opinion of the PI/designee) history of disease.
- •WBC (white blood cell) > 4.0 x 109/L and < 1.5 times the upper limit of normal (ULN), ANC (absolute neutrophil count) > 2.0 x 109/L and < 1.5 times the upper limit of normal (ULN), Platelet count > 150 x 109/L, AST (aspartate aminotransferase) < 2.5 time the upper limit of normal (ULN), ALT (alanine aminotransferase) < 2.5 time the upper limit of normal (ULN), Serum bilirubin < 1.5 time the upper limit of normal (ULN) and Serum creatinine < 1.5 time the upper limit of normal (ULN). [Refer to APPENDIX 1 for normal reference ranges]
- •The absence of febrile (defined by a documented oral temperature of 101.5 °F or greater) or infectious illness within 1 week of first dosing.
- •The absence of a clinically significant history of skin disorders, including psoriasis.
- •Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study, and for 30 days thereafter.
- •Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
- •Capable of consent.
- •Male subjects willing to follow approved birth control method for the duration of the study, and for 30 days thereafter, such as (a double barrier method) vasectomy, condom with spermicide, condom with diaphragm or abstinence, subject should also not donate sperm during this time.
排除标准
- •Positive test for hepatitis B, hepatitis C, or HIV.
- •Illicit/illegal drug use as evidenced by a positive test for alcohol or drug screen at screening or check -in.
- •Positive result for urine alcohol test at screening or check-in
- •Tobacco use as evidenced by a positive cotinine result at screening or check-in.
- •History of allergic reactions to pegfilgrastim, filgrastim, Escherichia coli (E. coli)-derived proteins, or other related drugs. History of allergic reactions or hypersensitivity to acetate/acetic acid, polysorbate 20, or sorbitol.
- •Hereditary fructose intolerance.
- •Females with positive pregnancy tests at screening or check-in.
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study or completing follow-up activities.
- •Clinically significant ECG or vital sign abnormalities at screening.
- •History of significant alcohol abuse within one year prior to initial dosing or regular use of alcohol (more than 14 units of alcohol per week) within six months prior to initial dosing.
- •History of drug abuse or use of illicit/illegal drugs within 1 year prior to initial dosing.
- •No medications are permitted during the study. Exceptions are:
- •Hormonal contraceptives and Hormone Replacement Therapy (HRT),
- •Thyroid replacement therapy i.e., liothyronine (T3) or levothyroxine (T4).
- •Acetaminophen
- •Donation of plasma within 7 days of dosing; blood donation or significant loss of blood within 30 days of dosing.
- •Participation in a clinical trial involving the administration of an investigational drug or marketed drug within 30 days prior to initial dosing (90 days for biologics) or concomitant participation in an investigational study involving no drug administration.
- •Females who are breast-feeding or lactating.
- •History of pulmonary infiltrate or pneumonia (radiologically confirmed) within 6 months prior to initial dosing.
- •Any past exposure to recombinant human G-CSF products and/or a known history of prior treatment with blood-cell colony stimulating factors, interleukins or interferons.
- •History of cancer
- •Subjects who are on a special diet or who have self-reported a weight loss of more than 15 pounds within 1 month prior to initial dosing.
- •Acute viral or bacterial infection within 1 month prior to initial dosing only if considered clinically significant in the opinion of the Principal Investigator/designee.
- •History of any clinically significant disease or condition that, in the opinion of the Principal Investigator/designee, would render them unsuitable for inclusion in the study.
- •Any vaccination (including influenza) within 90 days prior to initial dosing.
研究组 & 干预措施
TPI-120 (PEG-rhG-CSF)
PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
干预措施: PEG-rhG-CSF (Drug)
Neulasta (PEG-rhG-CSF)
Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
干预措施: Neulasta (PEG-rhG-CSF) (Drug)
结局指标
主要结局
Maximum observed concentration (Cmax)
时间窗: 56 days
To evaluate the pharmacokinetics
Area under the concentration-time curve from time zero to the time of the last non-zero concentration (AUC0-t)
时间窗: 56 days
To evaluate the pharmacokinetics
Area under the concentration-time curve from time zero to infinity (extrapolated AUC0-inf)
时间窗: 56 days
To evaluate the pharmacokinetics
次要结局
- Safety Variable - Tolerability as measured by Injection Site reactions(1, 2, 4, and 24 hours postdose during each study period)
- Safety Variable - Immunogenicity as measured by presence of Anti Drug Antibodies(Day 1 of each study period & Day 22 of each study period)
研究者
Dr. Apinya Vutikullid
principal investigator
Adello Biologics, LLC